Key Highlights
- SMMT shares rose 5.21% pre-market to $15.36, adding to a 3.11% gain in the prior session.
- Partner Akeso Inc. reported that ivonescimab monotherapy met the key secondary endpoint of overall survival in the HARMONi-2 study.
- The trial compared ivonescimab against pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer.
- The study's primary endpoint, progression-free survival, was already met in an earlier analysis with a hazard ratio of 0.51.
- One research firm reiterated a bullish rating with a $38 price target following the news.
Partner-Reported Survival Win Drives Pre-Market Gains
Summit Therapeutics (NASDAQ:SMMT) shares rose in pre-market trading after the company noted that its partner, Akeso Inc., announced positive overall survival results from the Phase 3 HARMONi-2 study. The trial, conducted entirely in China and sponsored by Akeso, evaluated ivonescimab as a monotherapy against pembrolizumab in patients with PD-L1-positive advanced or metastatic non-small cell lung cancer.
Summit Therapeutics is a clinical-stage biopharmaceutical company developing ivonescimab, a bispecific antibody targeting PD-1 with anti-angiogenic activity, across multiple late-stage trials in lung and colorectal cancers, both as a standalone treatment and in combination with chemotherapy.
Survival Benefit Builds on Earlier Progression-Free Survival Win
The overall survival result is a secondary endpoint in the study and builds on the trial's earlier primary endpoint finding, which showed a statistically significant improvement in progression-free survival for ivonescimab compared to pembrolizumab. Full results from the survival analysis are expected to be presented at an upcoming medical conference.
Summit carries a market Capitalization exceeding $11.65 billion, positioning it among the larger clinical-stage names in the oncology space. The company does not yet report positive earnings, reflecting its continued Investment in a broad late-stage trial program.
Data Generated Entirely by Chinese Partner Akeso
All data from the HARMONi-2 study was generated, managed, and analyzed by Akeso, which holds separate Marketing authorization for ivonescimab in China based on the trial's earlier results. Summit retains rights to develop and commercialize the drug in other territories, including through its own separately conducted late-stage trial in patients with high PD-L1 expression.
Global Lung Cancer Program Remains Central Investor Focus
The survival data adds to a string of positive readouts for ivonescimab across Summit's global development program, reinforcing investor confidence in the drug's competitive positioning against established checkpoint inhibitors. Attention now turns to the full data presentation and the ongoing separately run trial in high PD-L1 expressing patients as the next milestones for the program.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...